- Codexis and Nitto Denko Avecia have entered into an evaluation agreement to assess the ECO Synthesis® Manufacturing Platform.
- The collaboration aims to support the adoption of scalable, enzyme-catalysed oligonucleotide manufacturing methods.
Codexis, Inc., a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, has announced an evaluation agreement with Nitto Denko Avecia, Inc., a contract development and manufacturing organization (CDMO) specialising in oligonucleotide therapeutics.
Under the terms of the agreement, Nitto Denko Avecia will evaluate Codexis’ ECO Synthesis® Manufacturing Platform. The enzyme-based technology replaces traditional solid-phase oligonucleotide synthesis with a more flexible, enzyme-catalysed process designed for scalability. The collaboration may lead to future licensing discussions and wider adoption of the platform.
“We are excited to partner with Nitto Denko Avecia, a recognised leader in therapeutic oligonucleotide manufacturing. This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis® Manufacturing Platform, through best-in-class CDMO collaborations.”
Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis
Tammy Cooper, President at Nitto Denko Avecia, added that the evaluation reflects the company’s commitment to advancing next-generation manufacturing technologies and sustainable therapeutic development.
By combining Codexis’ ECO Synthesis® Platform with Nitto Denko Avecia’s large-scale manufacturing expertise, the companies aim to support scalable and sustainable production of oligonucleotide and siRNA-based therapeutics.
